Zepam (Bromazepam)

Quick links

Choose a section

Quick links to important sections

Advertisements

Zepam (Bromazepam)

Advertisements
Advertisements

Overview of Zepam (Bromazepam)

Property Description
Active ingredient Bromazepam (INN)
Form Oral dosage form (Tablet)
Pharmacological class Benzodiazepine, Anxiolytic
Common use Relief from severe or disabling anxiety
Origin Synthetic, Psychotropic substance

What Type of Drug is Bromazepam?

Bromazepam is a synthetic psychotropic drug classified within the Benzodiazepine family. It is recognized internationally as a substance subject to specific control due to its psychoactive nature. Bromazepam functions as a primary Central Nervous System (CNS) depressant. The single active ingredient is Bromazepam (INN), which is routinely prepared as an oral dosage form, specifically a tablet.

Pharmacological Classification and General Purpose

Bromazepam is clinically categorized as an anxiolytic, used for reducing anxiety and tension. Its essential purpose is to provide relief from intense, acute, or disabling states of anxiety that significantly impair daily function. The drug's physiological action is based on enhancing the effects of gamma-aminobutyric acid (GABA), the brain's main inhibitory neurotransmitter. By modulating the GABAA receptor, Bromazepam effectively diminishes excessive neural communication associated with agitation and pathological worry. This mechanism results in a stabilizing, calming effect. As a differentiating characteristic within the benzodiazepine class, Bromazepam is known for its intermediate action duration, distinguishing its kinetic profile from both ultrashort-acting and long-acting analogues.

Advertisements

What side effects are possible with Zepam (Bromazepam)?

Possible Side Effects and Safety Information

The official safety profile for Bromazepam is structured around effects on the Central Nervous System (CNS) and mandatory safety constraints, as documented in regulatory labeling. The most frequent or Common adverse reactions typically include drowsiness, dizziness, decreased alertness, and ataxia (impaired coordination). These effects are often noted at the start of treatment and usually lessen with continued use, consistent with the drug's classification as a CNS depressant.

Officially Documented Safety Concerns

The adverse reactions are grouped by the affected System Organ Class (SOC) in official documentation, including Nervous System Disorders (e.g., somnolence, amnesia) and Psychiatric Disorders (e.g., dependence, aggression).

Category Key Adverse Reactions (As per Regulatory Labels)
Serious Risks Profound sedation, respiratory depression (especially with co-use of CNS depressants like alcohol/opioids), convulsions (upon abrupt withdrawal), and increased risk of falls and fractures.
Time-Related Patterns Risk of dependence and withdrawal symptoms increases with both dose and duration of use. Risk of anterograde amnesia may increase at higher dosages.

Population-Specific Safety Constraints

The regulatory profile specifies precautions for certain patient groups. Older adults are at an increased risk of over-sedation, confusion, and falls. Bromazepam is contraindicated in patients with severe hepatic insufficiency (due to the risk of hepatic encephalopathy) and severe respiratory insufficiency. The use of the medicine exposes users to the risk of abuse, misuse, and addiction, which is a central feature of the safety information provided by governmental authorities.

Advertisements

Overdose and Emergency Response

Documented Overdose Manifestations

Overdose of Bromazepam is officially documented in regulatory information to present as dose-dependent Central Nervous System (CNS) depression. Clinical signs range from drowsiness, somnolence, lethargy, and confusion to physical impairment, including ataxia (lack of muscle coordination) and dysarthria (slurred speech). Dose-related toxicity may also result in decreased muscle tone (hypotonia).

Severe Outcomes and Required Emergency Action

Outcome/Action Official Regulatory Statement
Severe Complications Severe toxicity may escalate to profound sedation, loss of consciousness, coma, respiratory depression, and hypotension. The risk of life-threatening outcomes is significantly increased by co-ingestion with other CNS depressants, notably alcohol and opioids.
Mandatory Action Regulatory authorities require that immediate medical attention must be sought for any suspected overdose or for the manifestation of severe symptoms, such as profoundly slowed breathing or loss of consciousness. Urgent contact with emergency services is mandated.

Supportive Management

The primary management for overdose is symptomatic and supportive treatment, focused on the maintenance of respiration and cardiac function. A specific antidote, Flumazenil, is documented for use to reverse sedative effects; however, its administration is subject to a regulatory caution concerning the documented risk of inducing convulsions. Continued monitoring of vital signs is necessary, and overdose effects may be more pronounced in the elderly population.

Advertisements

Therapeutic Uses of Zepam (Bromazepam)

Bromazepam is generally applied when an anxiety disorder is severe, disabling, or subjecting the individual to extreme distress. The medication may be part of symptomatic management across therapeutic domains where additional support is needed to address significant patient discomfort. It is relevant in clinical settings for managing symptoms of severe anxiety, pathological apprehension, and the physical manifestations of high tension.

Symptomatic relief generally plays a role in managing difficult episodes, particularly when symptoms create noticeable interference with daily stability. It is commonly used to help manage psychological distress, somatic tension, and secondary sleep disturbance linked to intense anxiety.

“This medication is applied in addressing intense worry and inner turmoil that significantly interferes with a patient's daily comfort.”

This supportive relief assists with maintaining functional stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress.


Quick Fact: Relief for Severe Anxiety

Bromazepam is considered relevant in contexts marked by increased discomfort or tension and is used in areas where short-term symptom management is appropriate for disabling states of anxiety.

Regulatory References

  1. Summary of Product Characteristics (HPRA)
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zepam (Bromazepam) — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

  • Adults (typically 18 years of age and older).

Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to Bromazepam or other benzodiazepines.
  • Patients with Severe Respiratory Insufficiency or severe Sleep Apnoea Syndrome.
  • Patients with Myasthenia Gravis.
  • Patients with Severe Hepatic Insufficiency.

Age-related eligibility rules:

  • Pediatric Use: Not recommended for children and adolescents (generally under 18 years of age) due to insufficient data on safety and efficacy.
  • Older Adults (Geriatrics): Use requires special caution; the initial dose must be reduced.

Condition-specific eligibility rules:

  • Mild to Moderate Hepatic/Renal Impairment: Requires special caution, and the lowest possible dose should be given.
  • History of Alcohol or Drug Abuse: Use with extreme caution due to increased risk of dependence.

Pregnancy and lactation eligibility status (if explicitly documented):

  • Pregnancy: Use is not recommended.
  • Lactation (Breastfeeding): Use is contraindicated or not recommended.

Eligibility classifications (high-level)

Eligibility severity classification (as defined in official documents):

  • Absolute Prohibition (Contraindicated)
  • Conditional Prohibition (Not Recommended / Avoided)
  • Conditional Use (Caution Required / Dose Reduction Advised)

Resulting eligibility structure Official regulatory documents define who can and cannot use Bromazepam by establishing absolute contraindications based on severe organ failure, neuromuscular conditions, or hypersensitivity. Eligibility is restricted by age, with use not recommended for those under 18 and requiring lower doses for older adults. Furthermore, conditional eligibility is mandated for patients with non-severe organ impairment or a history of substance abuse, all as explicitly stated in the governmental labeling.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacodynamic Interactions and Restrictions

The most significant regulatory caution involves substances that cause additive Central Nervous System (CNS) depression. Co-administration with alcohol is officially not recommended due to the potential for severe sedation, respiratory, and cardiovascular depression. A severe regulatory warning exists for concomitant use with Opioids, which carries a documented risk of profound sedation, coma, and death. Other drug categories officially noted for this additive pharmacodynamic effect include antipsychotics, anticonvulsants, anxiolytics/sedatives, and sedative H1-antihistamines.

Pharmacokinetic Clearance Interactions

The drug’s clearance and exposure are sensitive to the inhibition of hepatic enzymes. Co-administration with strong CYP3A4 inhibitors is documented to increase the plasma concentration of Bromazepam by inhibiting its metabolic clearance. Specific medicines, such as Cimetidine and Fluvoxamine, are explicitly listed as modifying drug exposure. Cimetidine is documented to substantially reduce Bromazepam's clearance by approximately 50%, which can lead to prolonged elimination half-life.

Population-Specific Interaction Considerations

Official regulatory information notes specific cautions related to population groups. Special caution is required for elderly patients due to their increased susceptibility to pharmacodynamic interactions, including over-sedation. Caution is also mandated for individuals with mild to moderate hepatic impairment due to the potential for reduced drug clearance, which can heighten the severity of interactions.

Advertisements

Mechanism of Action

Bromazepam, a benzodiazepine, works by enhancing the signaling of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter within the central nervous system (CNS). This action reduces overall neuronal activity.


Positive Allosteric Modulation of GABA A Receptors

The drug functions as a positive allosteric modulator, binding to a specific site on the GABA A receptor complex distinct from the GABA binding site. This allosteric interaction increases the receptor’s affinity for GABA, facilitating a greater frequency of chloride channel opening. The resultant influx of chloride ions leads to hyperpolarization of the neuronal membrane, which diminishes the cell's responsiveness to excitatory stimuli.


Augmentation of Inhibitory Neurotransmission

By increasing chloride conductance and hyperpolarizing the neuron, Bromazepam augments the cascade of inhibitory neurotransmission. This mechanism results in a suppression of rapid and widespread excitatory signaling sequences, thereby inducing a state of reduced CNS excitability and overall physiological modulation within targeted pathways.

Advertisements

Dosage and Administration Information

Administration Guidelines and Dosage Schedule

Bromazepam is administered exclusively via the oral route using tablets, which are available in strengths such as 1.5 mg, 3 mg, and 6 mg. The usual daily dosage for outpatients in general practice is from 3 mg to 18 mg total, which is typically divided into two or three separate doses throughout the day. For severe cases or in hospitalized settings, higher doses may be given, potentially ranging from 6 mg to 12 mg per dose, up to a maximum daily dose of 60 mg in exceptional circumstances.

Usage Principle Instruction
Initiation and Adjustment Treatment should begin with the lowest effective dose and be gradually increased until the optimum level is achieved.
Timing Doses should preferably be taken on an empty stomach.
Duration Constraint The overall duration of therapy must be as short as possible and should not exceed 8 to 12 weeks, including the necessary tapering-off period.

Special Population Dosing

Standard clinical practice indicates that older adults (the elderly) must be given a reduced dose compared to the standard adult regimen, due to individual variations in sensitivity. Additionally, in patients with hepatic impairment, the lowest possible dose is advised, as benzodiazepines may contribute to other medical complications. Bromazepam is generally not indicated in children, but if used, the dosage must be determined and strictly monitored.

Discontinuation Protocol

Because of the risk of withdrawal symptoms, treatment must always be tapered off gradually once the decision is made to discontinue the medicine. The patient's condition and the necessity for continuing the medication should be regularly reassessed throughout the course of treatment.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Zepam (Bromazepam)

Evidence for use in Severe or Disabling Anxiety (Including GAD)

Research examining Bromazepam was primarily conducted in the context of severe anxiety, including conditions such as Generalized Anxiety Disorder (GAD). This research typically takes the form of short-term, randomized controlled trials (RCTs), which are often double-blind, consistent with established research standards. Studies explored outcomes related to measuring anxiety symptom severity using established rating scales and assessed how symptoms evolved over defined time intervals.

Findings describe patterns observed in these short-term studies, and research highlights changes measured during the study period when compared against control groups. Studies monitored outcomes related to physical discomfort and the systemic or functional imbalance linked to high anxiety. The level of certainty in the evidence is described as ranging from low to moderate, yet research has noted limitations.

Evidence for use in Specific Anxiety Contexts

Studies have also explored the use of Bromazepam in narrower clinical situations, such as Social Phobia (Social Anxiety Disorder). This evidence is generally derived from a limited number of specific, controlled trials. Research examined patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level, using specialized scales for these conditions.

In these specific contexts, the evidence level is described as low. This reflects the small sample sizes in dedicated trials. Furthermore, the research primarily focuses on short to intermediate-term observation, providing limited information for long-term outcomes in conditions marked by chronic functional limitations.

Duration of Studies and Follow-up

Most of the research for Bromazepam and the related drug class consists of studies observing short-term symptom patterns over defined time intervals, usually between 4 and 12 weeks. Dedicated research focusing on outcomes related to stability and flare-ups over many months is scarce. Therefore, information regarding long-term outcomes is not well characterized.

What is Still Uncertain About the Research Base

The available studies are limited by their generally short follow-up durations, resulting in a lack of comprehensive data on outcomes beyond 12 weeks. Long-term effects and the patterns observed over several years are not well established. The evidence quality varies across studies, and some subgroup findings are uncertain due to small sample sizes. Research provides context; its findings describe group patterns, not personal outcomes, and evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Summary of Product Characteristics (SmPC) for Lexotan (Bromazepam) - Health Products Regulatory Authority (HPRA)
  2. ATC/DDD Index N05BA08: Bromazepam (WHO Collaborating Centre for Drug Statistics Methodology)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Zepam (Bromazepam) (FAQ)

Q: Is Zepam (Bromazepam) considered a sleeping pill?

A: Bromazepam is officially classified as a benzodiazepine anxiolytic, meaning it is primarily used for anxiety and tension. However, due to its sedative properties, regulatory indications note that it may also be used in certain cases to address temporary insomnia.

Q: How long does it typically take to feel the effect of Zepam (Bromazepam)?

A: According to official pharmacodynamic profiles, the onset of action and peak effects of the medicine typically occur within 1 to 2 hours following administration of the tablet by mouth.

Q: Why do some people say Zepam (Bromazepam) makes them drowsy the next day?

A: According to official product information, drowsiness and decreased alertness are common central nervous system effects of Bromazepam, particularly at the start of treatment. While Bromazepam is an intermediate-acting medicine, residual effects can sometimes be noted, which relates to the duration of its activity in the body.

Q: Is Zepam (Bromazepam) meant to be taken every day?

A: The drug is intended for short-term use, generally not exceeding 8 to 12 weeks. Official prescribing information states that the total amount used each day is typically divided into two or three separate doses taken throughout the day for the duration of the treatment period.

Q: What should I know about driving while using Zepam (Bromazepam)?

A: Because Bromazepam may cause common side effects such as drowsiness, dizziness, and decreased alertness, regulatory warnings advise exercising caution. Users are cautioned about these effects when performing tasks that require full attention, such as driving or operating heavy machinery.

Q: Can Zepam (Bromazepam) affect mood in the long term?

A: Official documents note that the risk of dependence increases with the duration of use. Furthermore, psychiatric disorders, including unusual mood changes or paradoxical reactions like restlessness, have been documented in the regulatory safety profile. Research studies focusing on outcomes beyond 12 weeks of use are generally scarce.

Q: What is the relationship between Zepam (Bromazepam) and cognitive function?

A: Official regulatory information lists potential central nervous system effects that relate to cognitive function. These include decreased alertness, drowsiness, and a risk of anterograde amnesia (difficulty forming new memories), particularly when higher amounts are used.

Q: Can Zepam (Bromazepam) be taken with antacids?

A: Official information notes that antacids may interfere with the body's ability to absorb some benzodiazepines. Regulatory guidance on drug interactions suggests that antacids may delay the absorption and potentially reduce the peak concentration of the medicine.

Q: Are there any common foods to avoid while using Zepam (Bromazepam)?

A: Official drug interaction warnings note that the metabolism of Bromazepam can be sensitive to substances that inhibit hepatic enzymes. For this reason, some patient information contains advice against the consumption of grapefruit and grapefruit juice.

Q: Can Zepam (Bromazepam) interact with herbal supplements like St. John's Wort?

A: Regulatory documents caution about co-administering substances that affect the drug's metabolic clearance in the liver. Regulatory caution exists regarding herbal supplements, particularly St. John's Wort, as it is known to influence the same drug metabolism pathways.

Q: How quickly does the body eliminate Zepam (Bromazepam)?

A: Bromazepam is classified as having an intermediate action duration. Official information notes that its clearance, or rate of elimination from the body, can be substantially reduced by co-administered medications that inhibit hepatic enzymes, such as Cimetidine.

Q: What is the pregnancy safety category for Zepam (Bromazepam)?

A: Official regulatory documents state that use during pregnancy is not recommended due to documented risks to the developing fetus. Use during the third trimester and while breastfeeding is further contraindicated (absolutely prohibited).

Q: How does the time of day affect when Zepam (Bromazepam) is taken?

A: Official administration guidelines instruct that the total amount of the medicine used each day is typically to be divided and administered in two or three separate doses throughout the day.

Q: Is it normal to have vivid dreams while taking Zepam (Bromazepam)?

A: Official regulatory documentation does not specifically list 'vivid dreams' as an adverse effect. However, the regulatory safety profile does list nightmares among the possible psychiatric and paradoxical reactions associated with this class of medicine.

Q: Is Zepam (Bromazepam) used for pain relief?

A: Bromazepam is indicated for emotional disturbances and symptoms associated with severe anxiety. Regulatory documentation specifies its use for psychosomatic disorders (physical symptoms related to psychological factors), such as psychogenic headache, but it is not labeled for general pain relief.

Q: Do studies show Zepam (Bromazepam) is effective for panic attacks?

A: While the official indications focus on severe or disabling anxiety and functional disturbances, studies have also specifically examined the effectiveness of Bromazepam in treating conditions characterized by acute distress, such as panic attacks.

Q: Is it possible to take Zepam (Bromazepam) before surgery?

A: Benzodiazepines, as a class of medicine, are generally used in medical settings for their sedative properties. Official information exists regarding the use of reversal agents to manage sedation, which is a context where this class of medicine is generally used.

Q: Does Zepam (Bromazepam) show up on a drug test?

A: Bromazepam belongs to the benzodiazepine class. Official information on drug screening confirms that this class of medicine and its breakdown products are detectable in urine tests. The length of time it remains detectable can vary based on the specific drug's half-life.

Q: Is it true that Zepam (Bromazepam) can cause blurred vision?

A: Official regulatory consumer information lists blurred vision as a possible side effect, though it is not one of the most commonly experienced adverse reactions.

Q: Do caffeine or energy drinks affect Zepam (Bromazepam)?

A: Studies indicate that caffeine may antagonize, or work against, the sedative effects of this class of medicine. High intake of caffeine may potentially counter the calming action of the drug and may impact symptom control associated with anxiety.

Q: Can Zepam (Bromazepam) cause stomach upset?

A: Regulatory consumer information confirms that nausea or stomach upset is a possible side effect of Bromazepam, though it is considered one of the less common adverse reactions.

Q: Are headaches a noted side effect of Zepam (Bromazepam)?

A: Official regulatory consumer information lists headache as a possible side effect of Bromazepam, though it is generally considered a less common adverse reaction.

Q: Can Zepam (Bromazepam) affect blood pressure readings?

A: Regulatory consumer information confirms that hypotension (which means low blood pressure) is listed as a possible, though less common, side effect of Bromazepam.

Q: Can Zepam (Bromazepam) cause excessive sweating?

A: Regulatory information lists sweating as a potential symptom that may occur when a patient experiences withdrawal or sudden discontinuation of the treatment. It is not listed as a common side effect during the course of regular use.

Q: What have research studies found regarding the tolerance to Zepam (Bromazepam)?

A: Official regulatory information explicitly notes that tolerance, defined as a loss of response to the effects of the medicine, may develop. This typically occurs after the medicine has been used repeatedly for a prolonged period.

Q: Are there specific symptoms that mean Zepam (Bromazepam) is not working?

A: Regulatory information notes that tolerance—a gradual loss of the drug's intended effects—may develop after repeated use for a prolonged period. This is a potential sign that the treatment is no longer working as originally intended.

Q: Is Zepam (Bromazepam) commonly used in combination with antidepressants?

A: Regulatory warnings state that Bromazepam should not be used alone to treat depression or anxiety that is associated with depression. The warning clarifies that for depression or anxiety associated with depression, Bromazepam is not indicated for use alone.

Q: Is it safe to exercise heavily while taking Zepam (Bromazepam)?

A: Official information notes that the effects of benzodiazepines can include muscle weakness and reduced coordination. The official information advises caution during activities, particularly intensive physical efforts, due to the recognized risk of injury from impaired motor function.

Q: What are common patient misunderstandings about Zepam (Bromazepam) and anxiety?

A: Official regulatory documents contain warnings intended to clarify key misunderstandings, emphasizing that the drug is for short-term use only and that it carries a significant risk of dependence. These warnings clarify that the treatment is intended for severe or disabling anxiety, not for everyday stress.

Advertisements

How should Zepam (Bromazepam) be stored and disposed of?

How to Store and Dispose of Zepam (Bromazepam)

The official storage and disposal requirements for bromazepam tablets focus on maintaining product stability, ensuring child safety, and preventing misuse.


Official Storage Requirements

Bromazepam must be stored within the temperature constraint of below 30°C and should be protected from light and moisture. To maintain the product's integrity and protect it from environmental factors, it is required to keep the tablets in the original packaging until use.

Child Safety and Disposal Rules

Regulatory instructions mandate that the medicine must be stored out of the sight and reach of children to prevent accidental ingestion. When the medicine is no longer needed, it must not be thrown away via household waste or flushed down the toilet. Unused or expired bromazepam must be disposed of according to local regulatory requirements for pharmaceutical waste, often by returning it to a pharmacy or designated take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zepam (Bromazepam) found in:

A-Z Index: